Sleep-wake disturbances in Parkinson's disease: Current evidence regarding diagnostic and therapeutic decisions

European Neurology

Volumn 67, Issue 5, 2012, Pages 257-267

  Bruin, Veralice Meireles Sales ^a   Bittencourt, Lia Rita Azeredo ^b   Tufik, Sergio ^b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Circadian disorder; Insomnia; Parkinson's disease; Rapid eye movement sleep behavior disorder; Restless legs; Sleep apnea

Indexed keywords

ALPRAZOLAM; APOMORPHINE; BENZODIAZEPINE; BROMOCRIPTINE; CLONAZEPAM; ESZOPICLONE; GABAPENTIN; LEVODOPA; MELATONIN; NORTRIPTYLINE; OPIATE; OXYBATE SODIUM; PER1 PROTEIN; PRAMIPEXOLE; PREGABALIN; PROTEIN BMAL1; QUETIAPINE; REBOXETINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; ZOPICLONE;

BRAIN DEPTH STIMULATION; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DEMENTIA; DEPRESSION; DIAGNOSTIC IMAGING; DISEASE DURATION; DISEASE SEVERITY; FATIGUE; HUMAN; INSOMNIA; MUSCLE CRAMP; NARCOLEPSY; NIGHTMARE; NOCTURIA; PARASOMNIA; PARKINSON DISEASE; PERSONAL HYGIENE; PHOTOTHERAPY; PREVALENCE; PRIORITY JOURNAL; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDERED BREATHING; SLEEP QUALITY; SNORING; VISUAL HALLUCINATION; VIVID DREAM;

HUMANS; PARKINSON DISEASE; SLEEP DISORDERS;

EID: 84859112898     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000335078     Document Type: Review

References (154)

1. van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A: Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. Pharmacoepidemiol Drug Saf 2001; 10: 549-554.
2. Muangpaisan W, Hori H, Brayne C: Systematic review of the prevalence and incidence of Parkinson's disease in Asia. J Epidemio 2009; 19: 281-293.
3. Trenkwalder C, Schwarz J, Gebhard J, et al: Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson's disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neuro 1995; 52: 1017-1022.
4. von Campenhausen S, Bornschein B, Wick R, et al: Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmaco 2005; 15: 473-490.
5. Schoenberg BS: Environmental risk factors for Parkinson's disease: the epidemiologic evidence. Can J Neurol Sci 1987; 14: 407-413.
6. Checkoway H, Nelson LM: Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 1999; 10: 327-336.
7. Rouse ST, Marino MJ, Bradley SR, Awad H, Wittmann M, Conn PJ: Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. Pharmacol Ther 2000; 88: 427-435.
8. Tan SK, Hartung H, Sharp T, Temel Y: Serotonin- dependent depression in Parkinson's disease: a role for the subthalamic nucleus? Neuropharmacology 2011; 61: 387-399.
9. Poewe W: The natural history of Parkinson's disease. J Neurol 2006; 253(suppl 7):VII2- VII6.
10. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR: The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011; 26: 399-406.
11. Politis M, Wu K, Loane C, et al: Depressive symptoms in PD correlate with highe 5-HTT binding in raphe and limbic structures. Neurology 2010; 75: 1920-1927.
12. Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL: Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmaco 1982; 5: 183-194.
13. Margis R, Donis KC, Schonwald SV, Rieder CR: WHOQOL-OLD assessment of quality of life in elderly patients with Parkinson's disease: influence of sleep and depressive symptoms. Rev Bras Psiquiatr 2010; 32: 125-131.
14. Gallagher DA, Lees AJ, Schrag A: What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010; 25: 2493-2500.
15. Gunn DG, Naismith SL, Lewis SJ: Sleep disturbances in Parkinson disease and their potential role in heterogeneity. J Geriatr Psychiatry Neurol 2010; 23: 131-137.
16. Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, Logroscino G: Sleep disorders and the natural history of Parkinson's disease: the contribution of epidemiological studies. Sleep Med Rev 2011; 15: 41-50.
17. Menza M, Dobkin RD, Marin H, Bienfait K: Sleep disturbances in Parkinson's disease. Mov Disord 2010; 25(suppl 1):S117-S122.
18. Matuja WB, Aris EA: Motor and non-motor features of Parkinson's disease. East Afr Med J 2008; 85: 3-9.
19. Barone P, Antonini A, Colosimo C, et al: The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641-1649.
20. Wright JB: Mania following sleep deprivation. Br J Psychiatry 1993; 163: 679-680.
21. Gessa GL, Pani L, Fadda P, Fratta W: Sleep deprivation in the rat: an animal model of mania. Eur Neuropsychopharmacol 1995; 5(suppl):89-93.
22. Currie LJ, Bennett JP Jr, Harrison MB, Trugman JM, Wooten GF: Clinical correlates of sleep benefit in Parkinson's disease. Neurolog 1997; 48: 1115-1117.
23. Merello M, Hughes A, Colosimo C, Hoffman M, Starkstein S, Leiguarda R: Sleep benefit in Parkinson's disease. Mov Disord 1997; 12: 506-508.
24. Hogl B, Peralta C, Wetter TC, Gershanik O, Trenkwalder C: Effect of sleep deprivation on motor performance in patients with Parkinson's disease. Mov Disord 2001; 16: 616-621.
25. Forsaa EB, Larsen JP, Wentzel-Larsen T, Herlofson K, Alves G: Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord 2008; 23: 1420-1427.
26. Pal PK, Thennarasu K, Fleming J, Schulzer M, Brown T, Calne SM: Nocturnal sleep disturbances and daytime dysfunction in patients with Parkinson's disease and in their caregivers. Parkinsonism Relat Disord 2004; 10: 157-168.
27. Hogl B, Arnulf I, Comella C, et al: Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord 2010; 25: 2704-2716.
28. Norlinah MI, Afidah KN, Noradina AT, et al: Sleep disturbances in Malaysian patients with Parkinson's disease using polysomnography and PDSS. Parkinsonism Relat Disor 2009; 15: 670-674.
29. Buysse DJ, Reynolds CF, 3rd, Kupfer DJ, et al: Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD- 10 categories: a report from the APA/NIMH DSM-IV Field Trial. Sleep 1994; 17: 630-637.
30. McDonald WM, Richard IH, DeLong MR: Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatr 2003; 54: 363-375.
31. Naismith SL, Hickie IB, Lewis SJ: The role of mild depression in sleep disturbance and quality of life in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2010; 22: 384-389.
32. Gomez-Esteban JC, Tijero B, Somme J, et al: Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease. J Neurol 2011; 258: 494-499.
33. Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP: Insomnia in Parkinson's disease: frequency and progression over time. J Neurol Neurosurg Psychiatry 2007; 78: 476-479.
34. Suzuki K, Okuma Y, Hattori N, et al: Characteristics of sleep disturbances in Japanese patients with Parkinson's disease. A study using Parkinson's disease sleep scale. Mov Disord 2007; 22: 1245-1251.
35. Bugalho P, da Silva JA, Neto B: Clinical features associated with REM sleep behavior disorder symptoms in the early stages of Parkinson's disease. J Neurol 2011; 258: 50-55.
36. Prueksaritanond S, Boongird P, Pulkes T: Clinical features of familial Parkinson's disease in Thai patients. Qual Prim Care 2009; 17: 115-122.
37. Vibha D, Shukla G, Singh S, Goyal V, Srivastava AK, Behari M: Lower prevalence of sleep disturbances in familial versus sporadic Parkinson's disease: a questionnaire based study. J Neurol Sci 2010; 295: 27-30.
38. Bliwise DL, Watts RL, Watts N, Rye DB, Irbe D, Hughes M: Disruptive nocturnal behavior in Parkinson's disease and Alzheimer's disease. J Geriatr Psychiatry Neurol 1995; 8: 107-110.
39. Schäfer D, Greulich W: Effects of parkinsonian medication on sleep. J Neurol 2000; 247(suppl 4):IV/24-IV/27.
40. Unger MM, Belke M, Menzler K, et al: Diffusion tensor imaging in idiopathic rem sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep 2010; 33: 767-773.
41. Gama RL, Tavora DG, Bomfim RC, Silva CE, de Bruin VM, de Bruin PF: Sleep disturbances and brain MRI morphometry in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy - a comparative study. Parkinsonism Relat Disord 2010; 16: 275-279.
42. Iranzo A, Lomeña F, Stockner H, et al: Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2010; 9: 1070-1077.
43. Clarenbach P, Greulich W, Meinck HM, et al: Workshop I: Parkinson's disease and sleep - results of the group discussion. J Neuro 2000; 247(suppl 4):IV/34-IV/35.
44. Pacchetti C, Martignoni E, Terzaghi M, et al: Sleep attacks in Parkinson's disease: a clinical and polysomnographic study. Neurol Sc 2003; 24: 195-196.
45. Micallef J, Rey M, Eusebio A, et al: Antiparkinsonian drug-induced sleepiness: a double- blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol 2009; 67: 333-340.
46. Lees AJ: A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson's disease. Eur Neurol 1987; 27 (suppl 1):126-134.
47. Askenasy JJ, Yahr MD: Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study. Neurology 1985; 35: 527-532.
48. Leeman AL, O'Neill CJ, Nicholson PW, et al: Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 1987; 24: 637-643.
49. Block G, Liss C, Reines S, Irr J, Nibbelink D: Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37: 23-27.
50. Juri C, Chana P, Tapia J, Kunstmann C, Parrao T: Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol 2005; 28: 185-187.
51. Larsen JP, Tandberg E: Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs 2001; 15: 267-275.
52. Watts RL, Lyons KE, Pahwa R, et al: Onset of dyskinesia with adjunct ropinirole prolonged- release or additional levodopa in early Parkinson's disease. Mov Disord 2010; 25: 858-866.
53. Menza M, Dobkin RD, Marin H, et al: Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo. Mov Disord 2010; 25: 1708-1714.
54. Reuter I, Ellis CM, Ray Chaudhuri K: Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999; 100: 163-167.
55. Nodel MR: Effects of the dopamine agonist mirapex (pramipexole) therapy on sleep disorders in Parkinson's disease (in Russian). Zh Nevrol Psikhiatr Im S S Korsakova 2010; 110: 42-47.
56. Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, et al: Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. Eur J Neurol 2012; 19: 105-113.
57. Trenkwalder C, Kies B, Rudzinska M, et al: Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90-99.
58. Menza M, Dobkin RD, Marin H, et al: A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886-892.
59. Waters CH, Kurth M, Bailey P, et al: Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group. Neurology 1998; 50:S39-S45.
60. Arnulf I, Bejjani BP, Garma L, et al: Effect of low and high frequency thalamic stimulation on sleep in patients with Parkinson's disease and essential tremor. J Sleep Re 2000; 9: 55-62.
61. Romito LM, Scerrati M, Contarino MF, Iacoangeli M, Bentivoglio AR, Albanese A: Bilateral high frequency subthalamic stimulation in Parkinson's disease: long-term neurological follow-up. J Neurosurg Sci 2003; 47: 119-128.
62. Parkinson Study Group: A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60: 1721-1728.
63. Lyons KE, Friedman JH, Hermanowicz N, et al: Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol 2010; 33: 5-10.
64. Truong DD: Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging 2009; 4: 109-113.
65. Lemke MR: Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002; 63: 300-304.
66. Suzuki K, Miyamoto T, Miyamoto M, et al: Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson's disease. J Neurol Sci 2008; 271: 47-52.
67. Poryazova R, Benninger D, Waldvogel D, Bassetti CL: Excessive daytime sleepiness in Parkinson's disease: characteristics and determinants. Eur Neurol 2010; 63: 129-135.
68. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J: Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001; 57: 1392-1396.
69. O'suilleabhain PE, Dewey RB Jr: Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol 2002; 59: 986-989.
70. Braga-Neto P, da Silva-Junior FP, Sueli Monte F, de Bruin PF, de Bruin VM: Snoring and excessive daytime sleepiness in Parkinson's disease. J Neurol Sci 2004; 217: 41-45.
71. Korner Y, Meindorfner C, Moller JC, et al: Predictors of sudden onset of sleep in Parkinson's disease. Mov Disord 2004; 19: 1298-1305.
72. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP: Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 2006; 67: 853-858.
73. Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ: Nighttime sleep problems and daytime sleepiness in Parkinson's disease. Mov Disord 2008; 23: 35-41.
74. Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
75. Buysse DJ, Hall ML, Strollo PJ, et al: Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical/polysomnographic measures in a community sample. J Clin Sleep Med 2008; 4: 563-571.
76. Arnulf I: Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005; 9: 185-200.
77. Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O: Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment. Eur J Neurol 2005; 12: 199-207.
78. Rye DB, Bliwise DL, Dihenia B, Gurecki P: Fast track: daytime sleepiness in Parkinson's disease. J Sleep Res 2000; 9: 63-69.
79. Razmy A, Lang AE, Shapiro CM: Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004; 61: 97-102.
80. Fronczek R, Overeem S, Lee SY, et al: Hypocretin (orexin) loss and sleep disturbances in Parkinson's disease. Brain 2008; 131:e88.
81. Compta Y, Santamaria J, Ratti L, et al: Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 2009; 132: 3308-3317.
82. Sanjiv CC, Schulzer M, Mak E, et al: Daytime somnolence in patients with Parkinson's disease. Parkinsonism Relat Disord 2001; 7: 283-286.
83. Abbott RD, Ross GW, White LR, et al: Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurolog 2005; 65: 1442-1446.
84. Arnulf I, Konofal E, Merino-Andreu M, et al: Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58: 1019-1024.
85. Montastruc JL, Brefel-Courbon C, Senard JM, et al: Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol 2001; 24: 181-183.
86. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J: Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287: 455-463.
87. Ghorayeb I, Loundou A, Auquier P, Dauvilliers Y, Bioulac B, Tison F: A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. Mov Disord 2007; 22: 1567-1572.
88. Meindorfner C, Korner Y, Moller JC, Stiasny- Kolster K, Oertel WH, Kruger HP: Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord 2005; 20: 832-842.
89. Hogl B, Saletu M, Brandauer E, et al: Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a doubleblind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25: 905-909.
90. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J: Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disor 2003; 18: 287-293.
91. Weintraub D, Mavandadi S, Mamikonyan E, et al: Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010; 75: 448-455.
92. Ondo WG, Perkins T, Swick T, et al: Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol 2008; 65: 1337-1340.
93. Havlikova E, van Dijk JP, Rosenberger J, et al: Fatigue in Parkinson's disease is not related to excessive sleepiness or quality of sleep. J Neurol Sci 2008; 270: 107-113.
94. Bordet R, Devos D, Brique S, et al: Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol 2003; 26: 65-72.
95. Carrier J, Monk TH, Buysse DJ, Kupfer DJ: Inducing a 6-hour phase advance in the elderly: effects on sleep and temperature rhythms. J Sleep Res 1996; 5: 99-105.
96. Nyholm D, Lennernas H, Johansson A, Estrada M, Aquilonius SM: Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease. Clin Neuropharmaco 2010; 33: 181-185.
97. Fertl E: Comment to the paper of Medeiros CAM, et al. (2007) J Neurol 254: 459-464
98. Santiago PL, Rossi M, Cardinali DP, Merello M: Activity-rest rhythm abnormalities in Parkinson's disease patients are related to dopaminergic therapy. Int J Neurosc 2010; 120: 11-16.
99. Camara Magalhaes S, Vitorino Souza C, Rocha Dias T, Felipe Carvalhedo de Bruin P, de Bruin VM: Lifestyle regularity measured by the social rhythm metric in Parkinson's disease. Chronobiol Int 2005; 22: 917-924.
100. Cai Y, Liu S, Sothern RB, Xu S, Chan P: Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease. Eur J Neurol 2010; 17: 550-554.
101. Willis GL, Turner EJ: Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol Int 2007; 24: 521-537.
102. Paus S, Schmitz-Hubsch T, Wullner U, Vogel A, Klockgether T, Abele M: Bright light therapy in Parkinson's disease: a pilot study. Mov Disord 2007; 22: 1495-1498.
103. Postuma RB, Gagnon JF, Rompre S, Montplaisir JY: Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology 2010; 74: 239-244.
104. Montplaisir J, Gagnon JF, Fantini ML, et al: Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. Mov Disor 2010; 25: 2044-2051.
105. Cygan F, Oudiette D, Leclair-Visonneau L, Leu-Semenescu S, Arnulf I: Night-to-night variability of muscle tone, movements, and vocalizations in patients with REM sleep behavior disorder. J Clin Sleep Med 2010; 6: 551-555.
106. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF: REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010; 75: 494-499.
107. Ju YE, Larson-Prior L, Duntley S: Changing demographics in REM sleep behavior disorder: possible effect of autoimmunity and antidepressants. Sleep Med 2011; 12: 278-283.
108. Gagnon JF, Vendette M, Postuma RB, et al: Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann Neurol 2009; 66: 39-47.
109. Fantini ML, Farini E, Ortelli P, et al: Longitudinal study of cognitive function in idiopathic REM sleep behavior disorder. Slee 2011; 34: 619-625.
110. Lee JE, Kim KS, Shin HW, Sohn YH: Factors related to clinically probable REM sleep behavior disorder in Parkinson disease. Parkinsonism Relat Disord 2010; 16: 105-108.
111. De Cock VC, Vidailhet M, Leu S, et al: Restoration of normal motor control in Parkinson's disease during REM sleep. Brain 2007; 130: 450-456.
112. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J: REM sleep behaviour disorder in Parkinson's disease is associated with specific motor features. J Neurol Neurosurg Psychiatry 2008; 79: 1117-1121.
113. Stavitsky K, McNamara P, Durso R, Harris E, Auerbach S, Cronin-Golomb A: Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks. Cogn Behav Neuro 2008; 21: 143-149.
114. Arnulf I, Bonnet AM, Damier P, et al: Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurolog 2000; 55: 281-288.
115. Sinforiani E, Pacchetti C, Zangaglia R, Pasotti C, Manni R, Nappi G: REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: a two-year follow up. Mov Disord 2008; 23: 1441-1445.
116. Marion MH, Qurashi M, Marshall G, Foster O: Is REM sleep behaviour disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease? J Neurol 2008; 255: 192-196.
117. Terzaghi M, Sinforiani E, Zucchella C, et al: Cognitive performance in REM sleep behaviour disorder: a possible early marker of neurodegenerative disease? Sleep Me 2008; 9: 343-351.
118. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al: A 12-year population-based study of psychosis in Parkinson disease. Arch Neuro 2010; 67: 996-1001.
119. Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G: What predicts mortality in Parkinson disease? A prospective populationbased long-term study. Neurology 2010; 75: 1270-1276.
120. Pacchetti C, Manni R, Zangaglia R, et al: Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005; 20: 1439-1448.
121. International Classification of Sleep Disorders: Diagnostic and Coding Manual, ed 2. American Academy of Sleep Medicine. Westchester, 2005.
122. Frauscher B, Gschliesser V, Brandauer E, et al: REM sleep behavior disorder in 703 sleep-disorder patients: the importance of eliciting a comprehensive sleep history. Sleep Med 2010; 11: 167-171.
123. Gagnon JF, Postuma RB, Montplaisir J: Update on the pharmacology of REM sleep behavior disorder. Neurology 2006; 67: 742-747.
124. Boeve BF, Silber MH, Ferman TJ: Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results i 14 patients. Sleep Med 2003; 4: 281-284.
125. Sforza E, Krieger J, Petiau C: REM sleep behavior disorder: clinical and physiopathological findings. Sleep Med Rev 1997; 1: 57-69.
126. Anderson KN, Shneerson JM: Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 2009; 5: 235-239.
127. Fernandez HH, Okun MS, Rodriguez RL, et al: Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci 2009; 119: 2196-2205.
128. Yilmaz K, Kilincaslan A, Aydin N, Kor D: Prevalence and correlates of restless legs syndrome in adolescents. Dev Med Child Neurol 2011; 53: 40-47.
129. Allen RP, Walters AS, Montplaisir J, et al: Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 165: 1286-1292.
130. Nomura T, Inoue Y, Miyake M, Yasui K, Nakashima K: Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson's disease. Mov Disord 2006; 21: 380-384.
131. Juuti AK, Laara E, Rajala U, et al: Prevalence and associated factors of restless legs in a 57-year-old urban population in northern Finland. Acta Neurol Scand 2010; 122: 63-69.
132. Hanson M, Honour M, Singleton A, Crawley A, Hardy J, Gwinn-Hardy K: Analysis of familial and sporadic restless legs syndrome in age of onset, gender, and severity features. J Neurol 2004; 251: 1398-1401.
133. Araujo SM, de Bruin VM, Nepomuceno LA, et al: Restless legs syndrome in endstage renal disease: clinical characteristics and associated comorbidities. Sleep Me 2010; 11: 785-790.
134. Bastos JP, Sousa RB, Nepomuceno LA, et al: Sleep disturbances in patients on maintenance hemodialysis: role of dialysis shift. Rev Assoc Med Bras 2007; 53: 492-496.
135. Zucconi M, Ferini-Strambi L: Epidemiology and clinical findings of restless legs syndrome. Sleep Med 2004; 5: 293-299.
136. Moreira NC, Damasceno RS, Medeiros CA, et al: Restless leg syndrome, sleep quality and fatigue in multiple sclerosis patients. Braz J Med Biol Res 2008; 41: 932-937.
137. Manconi M, Ferini-Strambi L, Filippi M, et al: Multicenter case-control study on restless legs syndrome in multiple sclerosis: The REMS study. Sleep 2008; 31: 944-952.
138. Chou KJ, Chen PY, Huang MC: Restless legs syndrome following the combined use of quetiapine and paroxetine. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1139-1140.
139. Lopes LA, Lins Cde M, Adeodato VG, et al: Restless legs syndrome and quality of sleep in type 2 diabetes. Diabetes Care 2005; 28: 2633-2636.
140. Merlino G, Valente M, Serafini A, et al: Effects of restless legs syndrome on quality of life and psychological status in patients with type 2 diabetes. Diabetes Educ 2010; 36: 79-87.
141. Ondo WG, Vuong KD, Jankovic J: Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neuro 2002; 59: 421-424.
142. Garcia-Borreguero D, Odin P, Serrano C: Restless legs syndrome and PD: a review of the evidence for a possible association. Neurology 2003; 61:S49-S55.
143. Rye DB: Parkinson's disease and RLS: the dopaminergic bridge. Sleep Med 2004; 5: 317-328.
144. Iranzo A, Comella CL, Santamaria J, Oertel W: Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system. Mov Disord 2007; 22(suppl 18):S424-S430.
145. Happe S, Pirker W, Klosch G, Sauter C, Zeitlhofer J: Periodic leg movements in patients with Parkinson's disease are associated with reduced striatal dopamine transporter binding. J Neurol 2003; 250: 83-86.
146. Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M: Levodopa for restless legs syndrome. Cochrane Database Syst Rev 2011; 2:CD005504.
147. Chesson AL Jr, Wise M, Davila D, et al: Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 1999; 22: 961-968.
148. Happe S, Schrodl B, Faltl M, Muller C, Auff E, Zeitlhofer J: Sleep disorders and depression in patients with Parkinson's disease. Acta Neurol Scand 2001; 104: 275-280.
149. Noradina AT, Karim NA, Hamidon BB, Norlinah I, Raymond AA: Sleep-disordered breathing in patients with Parkinson's disease. Singapore Med J 2010; 51: 60-64.
150. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magalhaes MC, de Lourdes Seabra M, de Bruin VM: Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neuro 2007; 254: 459-464.
151. Diederich NJ, Vaillant M, Leischen M, et al: Sleep apnea syndrome in Parkinson's disease. A case-control study in 49 patients. Mov Disord 2005; 20: 1413-1418.
152. Trotti LM, Bliwise DL: No increased risk of obstructive sleep apnea in Parkinson's disease. Mov Disord 2010; 25: 2246-2249.
153. Cochen De Cock V, Abouda M, Leu S, et al: Is obstructive sleep apnea a problem in Parkinson's disease? Sleep Med 2010; 11: 247-252.
154. Monaca C, Ozsancak C, Jacquesson JM, et al: Effects of bilateral subthalamic stimulation on sleep in Parkinson's disease. J Neuro 2004; 251: 214-218.